规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
参考文献 |
1: Männistö PT, Hanhijärvi H, Kosma VM, Collan Y. A 6-month dermal toxicity test with dithranol and butantrone in miniature swine. Contact Dermatitis. 1986 Jul;15(1):1-9. doi: 10.1111/j.1600-0536.1986.tb01253.x. PMID: 2944694. 2: Göransson A. Comparison of dithranol and butantrone in short contact therapy of psoriasis. Acta Derm Venereol. 1987;67(2):149-53. PMID: 2438880. 3: Hanhijärvi H, Nevalainen T, Männistö P. A six month dermal irritation test with anthralins in the Göttingen miniature swine. Arch Toxicol Suppl. 1985;8:463-8. doi: 10.1007/978-3-642-69928-3_107. PMID: 3913406. 4: Remitz A, Kariniemi AL, Lehtonen E, Nordling S. Inhibition of proliferation of HeLa cells by dithranol (anthralin) and 1o-butyryl dithranol (butantrone). Br J Dermatol. 1989 Apr;120(4):525-31. doi: 10.1111/j.1365-2133.1989.tb01326.x. PMID: 2730843. 5: Brandt H. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). II. Clinical comparison of dithranol and butantrone sticks with special reference to side effects. Acta Derm Venereol. 1987;67(1):55-61. PMID: 2436415. 6: Remitz A. Short-contact therapy for psoriasis with 3.9% butantrone (10-butyryl dithranol). Acta Derm Venereol. 1989;69(4):351-4. PMID: 2568062. 7: Müller K, Gürster D. Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol). Biochem Pharmacol. 1993 Nov 17;46(10):1695-704. doi: 10.1016/0006-2952(93)90573-f. PMID: 8250955. 8: Viluksela M, Debets FM, van der Hoeven JC, Männistö PT. Dithranol (anthralin) and 10-butyryl dithranol (butantrone) do not morphologically transform cultured C3H 10T1/2 C18 mouse embryo fibroblasts. Acta Derm Venereol. 1994 Jan;74(1):54-6. doi: 10.2340/00015555745456. PMID: 7908485. 9: Göransson A. Irritation and staining by dithranol (anthralin) and butantrone (10-butyryl dithranol): further short contact and tape stripping experiments. Acta Derm Venereol. 1987;67(1):72-6. PMID: 2436419. 10: Viluksela M, Haasio K, Männistö PT. Studies on the contact sensitizing activity of dithranol (anthralin) and 10-butyryl dithranol (butantrone). Contact Dermatitis. 1990 Aug;23(2):103-10. doi: 10.1111/j.1600-0536.1990.tb03231.x. PMID: 2209005. 11: Männistö PT, Kirkland D, Viluksela M, Tikkanen L. Toxicological studies with dithranol and its 10-acyl analogues. Arch Toxicol. 1986 Oct;59(3):180-5. doi: 10.1007/BF00316330. PMID: 3813885. 12: Greaves MW. Irritation and staining by 10-butyryl dithranol (butantrone) in psoriasis. Int J Clin Pharmacol Res. 1986;6(4):315-6. PMID: 2428761. 13: Laakso S, Römer L, Mustakallio KK. Inhibition of soybean lipoxygenase-1 by 10-butyryl substituted 1,8-dihydroxy-9-anthrone (butantrone). Med Biol. 1986;64(1):43-5. PMID: 3088340. 14: Viluksela M, Puotunen E, Newman AJ, Männistö PT. Tumor-producing and skin- irritating activity of dithranol (anthralin) and its 10-acyl analogues in SENCAR mice. Carcinogenesis. 1986 Oct;7(10):1755-60. doi: 10.1093/carcin/7.10.1755. PMID: 3757176. 15: Göransson AM, Kolari PJ, Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds. V. Short-contact and tape-stripping experiments with dithranol and butantrone. Acta Derm Venereol. 1984;64(2):134-9. PMID: 6203301. 16: Mustakallio KK, Brandt H. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone). Acta Derm Venereol. 1984;64(1):63-6. PMID: 6203285. 17: Männistö PT, Vaissi L, Mustakallio KK, Viluksela M, Kosma VM, Collan Y. Tumor-producing activity of dithranol (anthralin) and two of its 10-acyl analogs in the dorsal skin of female NMRI mice. J Pharmacol Exp Ther. 1984 Apr;229(1):255-60. PMID: 6423812. 18: Männistö P, Havas A, Haasio K, Hanhijärvi H, Mustakallio K. Skin irritation by dithranol (anthralin) and its 10-acyl analogues in 3 animal models. Contact Dermatitis. 1984 Mar;10(3):140-5. doi: 10.1111/j.1600-0536.1984.tb00019.x. PMID: 6232099. 19: Rao K, Ch B, Narasu LM, Giri A. Antibacterial activity of Alpinia galanga (L) Willd crude extracts. Appl Biochem Biotechnol. 2010 Oct;162(3):871-84. doi: 10.1007/s12010-009-8900-9. Epub 2010 Apr 13. PMID: 20387130. 20: Mustakallio KK, Kolari PJ. Irritation and staining by dithranol (anthralin) and related compounds. IV. Visual estimation of erythema compared with contact thermometry and laser Doppler flowmetry. Acta Derm Venereol. 1983;63(6):513-8. PMID: 6198841.
|
---|
分子式 |
C18H16O4
|
---|---|
分子量 |
296.322
|
精确质量 |
296.1
|
元素分析 |
C, 72.96; H, 5.44; O, 21.60
|
CAS号 |
75464-11-8
|
SMILES |
O=C1C2=C(C=CC=C2O)C(C(CCC)=O)C3=CC=CC(O)=C13
|
InChi Key |
AHZXFRRDQXXPJD-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H16O4/c1-2-5-12(19)15-10-6-3-8-13(20)16(10)18(22)17-11(15)7-4-9-14(17)21/h3-4,6-9,15,20-21H,2,5H2,1H3
|
化学名 |
9(10H)-Anthracenone, 1,8-dihydroxy-10-(1-oxobutyl)-
|
别名 |
Butantrone; CCRIS2041; CCRIS-2041; CCRIS 2041
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体内) |
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。 注射用配方 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | |
5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | |
10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。